Search results for ''

The 2024 international workshop on Alport syndrome

14-16 March, 2024 – Nicosia, Cyprus
ENYO Pharma is sponsoring and will attend The 2024 International Workshop on Alport syndrome organized by the Alport Syndrome Alliance, an international patient-driven collaboration.

Published on 13/03/2024

ENYO Pharma announces a €39 million Series C financing and FDA clearance to advance Vonafexor in a Phase 2 clinical trial for patients with Alport syndrome

ENYO Pharma announces a €39 million Series C financing and FDA clearance to advance Vonafexor in a Phase 2 clinical trial for patients with Alport syndrome

Published on 03/01/2024

6th CKD Summit – Chronic Kidney Disease Drug Development

19-21 March, 2024
Boston, MA

ENYO Pharma will attend the 6th Chronic Kidney Disease Drug Development Summit, an industry forum sharing cross-industry insight to bring effective therapies to patients suffering from kidney diseases expanding also to rare renal disorders.

https://ckd3-summit.com/

Read more »

Published on 24/11/2023

ASN Kidney Week 2023

2-5 November 2023
Philadelphia, PA

ENYO Pharma will attend the world’s premier nephrology meeting of the American Society of Nephrology, ASN Kidney Week
https://www.asn-online.org/education/kidneyweek/

Read more »

Published on 09/10/2023

Alport Connect 2023, the annual Alport syndrome patient and family meeting in US

7-8 October, 2023
San Diego, CA

ENYO Pharma is sponsoring and will attend Alport Connect 2023 organized by the American Alport Syndrome Foundation (ASF) to meet patients and their family and present its Phase 2 clinical study planned with Vonafexor in Alport syndrome patients.

Alport Connect Meetings

Read more »

Published on 06/09/2023